The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling
Abstract
OBJECTIVE: Pathological gambling is a disabling disorder experienced by approximately 1%-2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. METHOD: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. RESULTS: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much improved" at the last evaluation, compared to 34.0% of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. CONCLUSIONS: Subjects who received nalmefene had a statistically significant reduction in severity of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Shaffer, H. J., Hall, M. N., & Vander Bilt, J. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.9.1369 · Cited by 1,253
Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling
Kim, S. W., Grant, J. E., Adson, D. E., & Shin, Y. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01079-4 · Cited by 503
Self-citationMatthews, R. T., & German, D. C. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90048-4 · Cited by 426
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1758 · Cited by 425
Naltrexone, an Antagonist for the Treatment of Heroin Dependence: Effects in Man
Martin, W. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360022003 · Cited by 392
A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling
Hollander, E., DeCaria, C. M., Finkell, J. N., Begaz, T., Wong, C. M., & Cartwright, C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00241-9 · Cited by 320
Self-citationA double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
Role of Dopamine D1and D2Receptors in the Nucleus Accumbens in Mediating Reward
Ikemoto, S., Glazier, B. S., Murphy, J. M., & McBride, W. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08580.1997 · Cited by 260
Hollander, E., Pallanti, S., Allen, A., Sood, E., & Rossi, N. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.137 · Cited by 228
Self-citationStewart, J. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(84)90017-0 · Cited by 211
Role of opioid antagonists in treating intravenous cocaine abuse
Kosten, T. R., Kleber, H. D., & Morgan, C. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90589-4 · Cited by 124
Broekkamp, C. L., Phillips, A. G., & Cools, A. R. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90137-0 · Cited by 122
Naltrexone-induced dysphoria in former opioid addicts
Crowley, T. J., Wagner, J., Zerbe, G. O., & Macdonald, M. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.9.1081 · Cited by 93
Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist
Dixon, R., Gentile, J., Hsu, H., Hsiao, J. H., Howes, J. F., Garg, D. C., & Weidler, D. J. (1987) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1987.tb02191.x · Cited by 78
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (2003) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.1.2.183 · Cited by 41
Salvato, F. R., & Mason, B. J. (1994) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1994.tb00102.x · Cited by 11
Cited by
Introduction to Behavioral Addictions
Grant, J. E., Potenza, M. N., Weinstein, A., & Gorelick, D. A. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.491884 · Cited by 1,242
Self-citationThe dopamine theory of addiction: 40 years of highs and lows
Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3939 · Cited by 649
The neurobiology and genetics of impulse control disorders: Relationships to drug addictions
Brewer, J. A., & Potenza, M. N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.043 · Cited by 511
Self-citationThe neurobiology of pathological gambling and drug addiction: an overview and new findings
Potenza, M. N. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0100 · Cited by 508
Self-citationA unified framework for addiction: Vulnerabilities in the decision process
Redish, A. D., Jensen, S., & Johnson, A. (2008) · Behavioral and Brain Sciences · doi:10.1017/s0140525x0800472x · Cited by 501
Metadata
- Authors
- Grant, J. E., Potenza, M. N., Hollander, E., Cunningham-Williams, R., Nurminen, T., Smits, G., & Kallio, A.
- Venue
- American Journal of Psychiatry
- Published
- 2006-02-01
- Volume
- 163
- Issue
- 2
- Pages
- 303-312
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2119974740
- Cited by
- 364
- References
- 17
- FWCI
- 31.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.